Given that sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated significant benefits in the treatment of heart failure, including cases with preserved ejection fraction, particularly in patients with concurrent diabetes, they may emerge as a recommended treatment option. The gene discussed is SLC5A2; the disease is diabetes mellitus.